Gilead donated 1.5 million vials of the drug, the first to receive emergency authorization by the FDA to treat COVID-19, to the government. But the first batch was given to hospitals with no intensive care units, and therefore no eligible patients, and to hospitals without the refrigeration needed to store it, meaning some had to be returned to the government, nine current and former senior administration officials told the Post.
The initial batch consisted of 607,000 vials of remdesivir and was sent to hospitals in 13 states. Many hospitals weren’t prepared to receive the drug because they weren’t told they’d be receiving it beforehand, according to the Post.
The federal government had been allocating the drug itself, but on May 5 it said it would start sending the drug to states, which would then decide which hospitals would get it. State officials told the Post the new system has “greatly improved” the distribution process.
Read the full article here.
More articles on pharmacy:
6 BCBS companies sue CVS, claiming decadelong insurance fraud scheme
FDA finds carcinogen in popular diabetes drug
Georgia pharma company recalls thyroid drug for super potency
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.